These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 25776529)

  • 61. 6-Amino-2,4,5-trimethylpyridin-3-ol and 2-amino-4,6-dimethylpyrimidin-5-ol derivatives as selective fibroblast growth factor receptor 4 inhibitors: design, synthesis, molecular docking, and anti-hepatocellular carcinoma efficacy evaluation.
    Chaudhary CL; Lim D; Chaudhary P; Guragain D; Awasthi BP; Park HD; Kim JA; Jeong BS
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):844-856. PubMed ID: 35296193
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models.
    French DM; Lin BC; Wang M; Adams C; Shek T; Hötzel K; Bolon B; Ferrando R; Blackmore C; Schroeder K; Rodriguez LA; Hristopoulos M; Venook R; Ashkenazi A; Desnoyers LR
    PLoS One; 2012; 7(5):e36713. PubMed ID: 22615798
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies.
    Lang L; Teng Y
    Cells; 2019 Jan; 8(1):. PubMed ID: 30634399
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Discovery of Novel 7-Azaindole Derivatives as Selective Covalent Fibroblast Growth Factor Receptor 4 Inhibitors for the Treatment of Hepatocellular Carcinoma.
    Zhong Z; Shi L; Fu T; Huang J; Pan Z
    J Med Chem; 2022 May; 65(10):7278-7295. PubMed ID: 35549181
    [TBL] [Abstract][Full Text] [Related]  

  • 65. IL-1β inhibits β-Klotho expression and FGF19 signaling in hepatocytes.
    Zhao Y; Meng C; Wang Y; Huang H; Liu W; Zhang JF; Zhao H; Feng B; Leung PS; Xia Y
    Am J Physiol Endocrinol Metab; 2016 Feb; 310(4):E289-300. PubMed ID: 26670488
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target.
    Liu WY; Xie DM; Zhu GQ; Huang GQ; Lin YQ; Wang LR; Shi KQ; Hu B; Braddock M; Chen YP; Zheng MH
    Expert Opin Ther Targets; 2015 May; 19(5):675-85. PubMed ID: 25547779
    [TBL] [Abstract][Full Text] [Related]  

  • 67. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
    Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
    J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
    [TBL] [Abstract][Full Text] [Related]  

  • 68. FGFR4 Inhibitor BLU9931 Attenuates Pancreatic Cancer Cell Proliferation and Invasion While Inducing Senescence: Evidence for Senolytic Therapy Potential in Pancreatic Cancer.
    Sasaki N; Gomi F; Yoshimura H; Yamamoto M; Matsuda Y; Michishita M; Hatakeyama H; Kawano Y; Toyoda M; Korc M; Ishiwata T
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33066597
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Making way for suppressing the FGF19/FGFR4 axis in cancer.
    Prieto-Dominguez N; Shull AY; Teng Y
    Future Med Chem; 2018 Oct; 10(20):2457-2470. PubMed ID: 30325210
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-
    Yang F; Chen X; Song X; Ortega R; Lin X; Deng W; Guo J; Tu Z; Patterson AV; Smaill JB; Chen Y; Lu X
    J Med Chem; 2022 Nov; 65(21):14809-14831. PubMed ID: 36278929
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Design, Synthesis, and Biological Evaluation of 2-Formyl Tetrahydronaphthyridine Urea Derivatives as New Selective Covalently Reversible FGFR4 Inhibitors.
    Zhang Z; Li J; Chen H; Huang J; Song X; Tu ZC; Zhang Z; Peng L; Zhou Y; Ding K
    J Med Chem; 2022 Feb; 65(4):3249-3265. PubMed ID: 35119278
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma.
    Gauglhofer C; Paur J; Schrottmaier WC; Wingelhofer B; Huber D; Naegelen I; Pirker C; Mohr T; Heinzle C; Holzmann K; Marian B; Schulte-Hermann R; Berger W; Krupitza G; Grusch M; Grasl-Kraupp B
    Carcinogenesis; 2014 Oct; 35(10):2331-8. PubMed ID: 25031272
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation.
    Luo Y; Yang C; Lu W; Xie R; Jin C; Huang P; Wang F; McKeehan WL
    J Biol Chem; 2010 Sep; 285(39):30069-78. PubMed ID: 20657013
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Design, synthesis, and anticancer evaluation of arylurea derivatives as potent and selective type II irreversible covalent FGFR4 inhibitors.
    Wang M; Lan L; Wang YW; Zhang JY; Shi L; Sun LP
    Bioorg Med Chem; 2023 May; 87():117298. PubMed ID: 37196426
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4.
    Chen X; Li H; Lin Q; Dai S; Qu L; Guo M; Zhang L; Liao J; Wei H; Xu G; Jiang L; Chen Y
    Eur J Med Chem; 2024 Mar; 268():116281. PubMed ID: 38432058
    [TBL] [Abstract][Full Text] [Related]  

  • 76. FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis.
    Chen T; Liu H; Liu Z; Li K; Qin R; Wang Y; Liu J; Li Z; Gao Q; Pan C; Yang F; Zhao W; Zhang Z; Xu Y
    Oncogene; 2021 Jul; 40(30):4941-4953. PubMed ID: 34163030
    [TBL] [Abstract][Full Text] [Related]  

  • 77. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways.
    Wu AL; Coulter S; Liddle C; Wong A; Eastham-Anderson J; French DM; Peterson AS; Sonoda J
    PLoS One; 2011 Mar; 6(3):e17868. PubMed ID: 21437243
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT.
    Sass G; Klinger N; Sirma H; Hashemolhosseini S; Hellerbrand C; Neureiter D; Wege H; Ocker M; Tiegs G
    Int J Oncol; 2011 Aug; 39(2):433-42. PubMed ID: 21567083
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.
    Yang C; Jin C; Li X; Wang F; McKeehan WL; Luo Y
    PLoS One; 2012; 7(3):e33870. PubMed ID: 22442730
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.